MedTrace Logo

Tadalafil-Delivra and Raynaud's Phenomenon

NCT03393325 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-09-20

No results posted yet for this study

Summary

A 4-8 week observational feasibility study of the use of the use of Tadalafil-Delivra in the treatment of Reynaud's Phenomena (RP).

Conditions

  • Raynaud Phenomenon

Interventions

OTHER

Observation of treatment with Tadalafil-Delivra

Tadalafil 2% in a Delivra base (Transdermal Application)

Sponsors & Collaborators

  • Delivra, Inc.

    collaborator INDUSTRY

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Janet E Pope, MD PhD · St. Joseph's Health Care, London, ON

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2019-06-30
Completion
2019-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03393325 on ClinicalTrials.gov